Abstract
We agree that information regarding long-term use of hydroxychloroquine and coronavirus disease 2019 (COVID-19) outcomes is needed. When reporting a case to the COVID-19 Global Rheumatology Alliance registry, providers are asked to report on various medications taken before the patient had COVID-19. Although specific details on individual medications might not have been included in our Comment,1 we report the percentage of cases on a number of immunomodulatory and immunosuppressive drugs, including antimalarials, on a weekly basis to our website, Twitter account, and mailing list, so these data are widely accessible and regularly updated.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call